Recida Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of novel-class antibiotics to address the expanding problem of multi-drug resistant gram-negative bacteria. Treatment of infections caused by resistant gram-negative bacteria — especially Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii– is recognized as an unmet medical need by the global infectious diseases community. No new class of anti-gram-negative agents has been successfully developed in fifty years. There is a clear unmet medical need for antibiotics with a new mechanism of action against these potentially deadly pathogens.
Recida’s lead product, RC-01, is a novel LpxC inhibitor exhibiting potent in vitro and in vivo antibacterial activity against drug-resistant gram-negative bacteria, including many that are highly resistant to currently available antibiotics. RC-01 has demonstrated a favorable preclinical pharmacokinetic and efficacy profile as well as an excellent preclinical safety profile in animals. In addition, RC-01 has unique antibacterial features that make it highly differentiated from currently marketed drugs. RC-01 is currently under development as an intravenous formulation enabling its use in the hospital to treat serious infections caused by target organisms. A Phase 1 study is planned to evaluate the safety and pharmacokinetic profiles of RC-01 Injection in humans.
